DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $18,220 | -6.6% | 78,075 | -0.7% | 0.30% | -15.4% |
| Q3 2023 | $19,502 | +3.3% | 78,607 | +0.1% | 0.35% | +7.4% |
| Q2 2023 | $18,874 | +2.0% | 78,553 | +7.1% | 0.33% | -8.7% |
| Q1 2023 | $18,502 | -7.2% | 73,330 | -2.3% | 0.36% | -11.0% |
| Q4 2022 | $19,941 | -99.9% | 75,059 | -1.3% | 0.40% | -5.2% |
| Q3 2022 | $19,666,000 | +0.1% | 76,067 | -1.7% | 0.42% | +6.3% |
| Q2 2022 | $19,637,000 | -15.8% | 77,383 | -2.6% | 0.40% | -2.5% |
| Q1 2022 | $23,327,000 | -13.7% | 79,458 | -3.3% | 0.41% | -11.1% |
| Q4 2021 | $27,044,000 | +8.9% | 82,146 | +0.7% | 0.46% | -3.2% |
| Q3 2021 | $24,837,000 | +7.5% | 81,584 | -5.2% | 0.47% | +7.5% |
| Q2 2021 | $23,101,000 | +17.8% | 86,081 | -1.2% | 0.44% | +11.6% |
| Q1 2021 | $19,612,000 | -8.8% | 87,134 | -10.0% | 0.40% | -13.9% |
| Q4 2020 | $21,497,000 | +1.5% | 96,771 | -1.6% | 0.46% | -7.6% |
| Q3 2020 | $21,172,000 | +19.8% | 98,322 | -1.6% | 0.50% | +7.6% |
| Q2 2020 | $17,672,000 | +24.2% | 99,936 | -2.8% | 0.46% | +6.5% |
| Q1 2020 | $14,226,000 | -10.4% | 102,778 | -6.5% | 0.43% | +4.1% |
| Q3 2019 | $15,875,000 | +6742.7% | 109,914 | +6672.3% | 0.42% | +4533.3% |
| Q2 2019 | $232,000 | +8.4% | 1,623 | 0.0% | 0.01% | +12.5% |
| Q1 2019 | $214,000 | +28.9% | 1,623 | +0.7% | 0.01% | +14.3% |
| Q4 2018 | $166,000 | -5.1% | 1,611 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $175,000 | +218.2% | 1,611 | +187.2% | 0.01% | +250.0% |
| Q2 2018 | $55,000 | 0.0% | 561 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $55,000 | -31.2% | 561 | -34.8% | 0.00% | -33.3% |
| Q4 2017 | $80,000 | +8.1% | 861 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $74,000 | +1.4% | 861 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $73,000 | -15.1% | 861 | -14.4% | 0.00% | -25.0% |
| Q1 2017 | $86,000 | +10.3% | 1,006 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $78,000 | +105.3% | 1,006 | +109.1% | 0.00% | +100.0% |
| Q3 2016 | $38,000 | -30.9% | 481 | -11.3% | 0.00% | -33.3% |
| Q2 2016 | $55,000 | +77.4% | 542 | +63.7% | 0.00% | +50.0% |
| Q1 2016 | $31,000 | 0.0% | 331 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $31,000 | +10.7% | 331 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $28,000 | -55.6% | 331 | -54.7% | 0.00% | -33.3% |
| Q2 2015 | $63,000 | +1.6% | 731 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $62,000 | +121.4% | 731 | +120.8% | 0.00% | +200.0% |
| Q4 2014 | $28,000 | +12.0% | 331 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $25,000 | -3.8% | 331 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $26,000 | +136.4% | 331 | +120.7% | 0.00% | 0.0% |
| Q1 2014 | $11,000 | +266.7% | 150 | +226.1% | 0.00% | – |
| Q3 2013 | $3,000 | – | 46 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |